MedPath

Influence of a Prematuration Culture With a Phosphodiesterase-3 Inhibitor (PDE3-I) on Embryonic Aneuploidy Rate and Developmental Potential

Phase 1
Terminated
Conditions
Infertility
Interventions
Procedure: prematuration culture
Registration Number
NCT00823420
Lead Sponsor
Universitair Ziekenhuis Brussel
Brief Summary

A single centre randomised controlled trial investigating the influence of a novel prematuration system (PMS) using a phosphodiesterase-3 inhibitor for in-vitro maturation of oocytes

Detailed Description

Not available

Recruitment & Eligibility

Status
TERMINATED
Sex
Female
Target Recruitment
213
Inclusion Criteria
  • healthy volunteers, either with PCOS/PCOS-like ovaries, or with normal ovaries, who undergo oocyte donation for research
  • AFC at least 10
  • AMH: > 5 μg/L
  • Female age < 36 years
Read More
Exclusion Criteria
  • major uterine or ovarian abnormalities
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
in-vitro maturation of oocytesprematuration culture-
Primary Outcome Measures
NameTimeMethod
Incidence of aneuploidy rate by fluorescence in situ hybridisation (FISH) technique in 6 to 8 cell embryos from prolonged (PMC) IVM compared to conventional IVM on sibling oocytes.3 days after egg retrieval
Secondary Outcome Measures
NameTimeMethod
Implantation potential of embryos from conventional IVM performed on Type II COC. Efficiency of both maturation systems in obtaining blastocysts. Endometrium quality in IVM cycles.7 days after egg retrieval

Trial Locations

Locations (1)

Centre for Reproductive Medicine

🇧🇪

Brussels, Belgium

© Copyright 2025. All Rights Reserved by MedPath